KDIGO clinical practice guidelines for diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) recommend lowering high serum Phosphate (P) and Parathyroid Hormone (PTH), as well as maintaining normal Calcium (Ca). These parameters are used as proxies for end-organ damage to the skeletal (bone resorption) and cardiovascular (vascular calcification) system. We have previously presented a Quantitative System Pharmacology (QSP) model of CKD-MBD and demonstrated its use therapeutic hypothesis testing capacity in designing a treatment strategy that explicitly minimizes abnormal mineral movement in CKD-5D patients. To further advance the treatment of CKD-MBD, we now investigate which biochemical parameters associate with vascular calcification, quantified by Coronary Artery Calcification (Agatston) score.